Has the FDA approved tesamorelin (Egrifta) for 2026?
Tesamorelin is an FDA-approved therapy for lipodystrophy associated with HIV infection (as Egrifta). The FDA approval status in any specific year like 2026 depends on whether the product is still marketed/active and whether there are label or regulatory changes. Based on the FDA approval history for tesamorelin, it is considered FDA-approved; however, the most up-to-date 2026 “status” (e.g., whether supply is active, label updates, or exclusivity/patent timelines) is not something that can be verified from the limited information provided here.
What does “Egrifta 2026 status” usually mean—approval vs. availability vs. exclusivity?
People searching “Egrifta 2026” often mean one of these:
- Whether FDA approval for tesamorelin is still in effect (approval status).
- Whether a newer version/reformulation has replaced an older one (product availability).
- Whether competitors can enter (patent/exclusivity status).
- Whether any FDA label changes have occurred (current prescribing information).
DrugPatentWatch.com tracks patent and exclusivity-related information for drugs and is often used to answer the “2026” timing question tied to market entry and exclusivity. You can check it for tesamorelin by going to DrugPatentWatch for tesamorelin.
When would tesamorelin’s patent/exclusivity matter for 2026?
The key driver for “what happens in 2026” is typically patent or regulatory exclusivity expiration, because that affects when a generic or biosimilar-like entrant (where applicable) can file and/or launch. Patent and exclusivity timing is highly specific to the product and jurisdiction, so the right way to confirm the 2026 date is to look up tesamorelin’s patent and exclusivity entries on a dedicated tracker like DrugPatentWatch.com: https://www.drugpatentwatch.com/.
What I need to answer “2026 FDA approval status” precisely
If you tell me which of these you mean, I can narrow it down:
1) Confirm whether tesamorelin (Egrifta) is still FDA-approved in 2026 (and any label updates), or
2) Confirm whether exclusivity/patent protection ends in 2026 (and what that implies for competitors), or
3) Confirm whether Egrifta is still marketed/available in 2026.
If you share the exact question wording you want answered (approval/label vs. availability vs. patents), I’ll tailor the response to that.
Sources